For patients with non-curative resection after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), complementary surgery is generally recommended. However, about 2/3 of patients have no remaining tumor in the stomach or regional lymph nodes. In this trial, Indocyanine Green (ICG)-guided lymphadenectomy with or without laparoscopic and endoscopic cooperative surgery (LECS) will be tested as a less invasive alternative in such cases. For patients with a primary radically resected EGC, ICG-guided lymphadenectomy alone will be performed. For patients with deep-margin positive EGC, ICG-guided lymphadenectomy and LECS will be performed, in order to ensure both local tumor control in the stomach and in regional nodes.
Endoscopic submucosal dissection (ESD) is the recommended treatment for early gastric cancer (EGC) who are fullfillling the criteria based on international guidelines. After ESD, some resections are classified as non-curative because of factors such as non radicality (especially when the deep margin is positive for cancer), lymphovascular invasion or deep submucosal invasion Sm\>1. In such cases, guidelines recommend complementary gastrectomy and lymphadenectomy. Gastrectomy is known to carry a risk for severe complications in about 9-22 % of cases. Furthermore, up to 2/3 of patients are found to have no remaining tumor in the stomach or regional nodes after surgery. In this trial, Indocyanine Green (ICG)-guided lymphadenectomy including sentinel node resection, with or without complementary laparoscopic and endoscopic cooperative surgery (LECS) will be tested as a less invasive treatment option. For patients with radically resected EGC, ICG-guided lymphadenectomy alone will be performed. In patients with deep margin positive EGC, ICG-guided lymphadenectomy and LECS will be performed. ICG-guided lymphadenectomy is performed by first injecting 100 times diluted ICG in four quadrants in the submucosa around the tumor scar with gastroscopy. After 15 minutes, the draining nodes will be visualized with laparoscopy, and locally resected. LECS is performed by endoscopic marking of the scar followed circumferential mucosal cutting, trimming, and perforation of the stomach followed by full-thickness resection of the scar with laparoscopy. After resection, the resected specimen will be taken out and the stomach defect sutured laparoscopically. After the procedure, the patient will be presented at a multidisciplinary tumor board. If only clinical follow-up is recommended, the patient will be followed closely with gastroscopy and computer tomography (CT) scan every 3 months for the first year.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Submucosal injection of ICG in quadrants around the scar after ESD, followed by laparoscopic resection of positive lymph nodes after 15 minutes
Endoscopic marking and submucosal cutting around the scar after ESD, followed by perforation of the gastric wall and laparoscopic full thickness resection of the area under endoscopic guidance.
Karolinska University Hospital Huddinge
Stockholm, Sweden
Severe complications defined as Clavien-Dindo >/= III
Safety of the procedure, defined as Clavien-Dindo complication grade \>/= III
Time frame: Periprocedural
Any complications
Any complication during the procedure (Clavien-Dindo II-IV)
Time frame: Periprocedural
Postoperative bleeding
Postoperative bleeding requiring blood transfusion
Time frame: Periprocedural
Leakage
Leakage/postoperative abscess requiring drainage
Time frame: Periprocedural
Operation time
Time of the surgical procedure
Time frame: Periprocedural
Pathological tumor (T)-stage
Depth of tumor invasion into the gastric wall (for LECS cases)
Time frame: Up to 2 months post procedure
Tumor-free resection margins
The rate of horizontal and vertical margins free of tumor cells (for LECS cases).
Time frame: Up to 2 months post procedure
Number of lymph nodes
Number of lymph nodes harvested during the procedure
Time frame: Periprocedural
Number of positive lymph nodes
Number of lymph nodes positive for cancer
Time frame: Up to 2 months post procedure
Hospital-stay
Number of days from the procedure until discharge
Time frame: From the day of the procedure until patient is discharged from the hospital, assessed up to 12 weeks post procedure
Health-related quality of life (HQL) score QLQ-30
Pre and postoperative HQL, tested with the validated score QLQ-C30 (The EORTC QLG Core Questionnaire for cancer patients)
Time frame: Preoperatively, after 30 days and 1 year
Health-related quality of life (HQL) score OG25
Pre and postoperative HQL, tested with the validated score OG25 (The EORTC QLG Module Questionnaire specifically for esophago-gastric patients)
Time frame: Preoperatively, after 30 days and 1 year
30-day mortality
30-day mortality
Time frame: From procedure to maximum 30 days postoperatively
In-hospital mortality
In-hospital mortality
Time frame: From the day of the procedure until patient is discharged from the hospital, assessed up to 12 weeks post procedure
1-year disease-free survival
1-year disease-free survival
Time frame: Until 1 year after the procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.